

Psychological Assessment

Using the Center for Epidemiologic Studies Depression Scale to Assess Depression in Women With HIV and Women at Risk for HIV: Are Somatic Items Invariant?

Leah M. Adams, Tracey E. Wilson, Daniel Merenstein, Joel Milam, Jennifer Cohen, Elizabeth T. Golub, Adebola Adedimeji, and Judith A. Cook

Online First Publication, February 23, 2017. <http://dx.doi.org/10.1037/pas0000456>

CITATION

Adams, L. M., Wilson, T. E., Merenstein, D., Milam, J., Cohen, J., Golub, E. T., Adedimeji, A., & Cook, J. A. (2017, February 23). Using the Center for Epidemiologic Studies Depression Scale to Assess Depression in Women With HIV and Women at Risk for HIV: Are Somatic Items Invariant?. *Psychological Assessment*. Advance online publication. <http://dx.doi.org/10.1037/pas0000456>

Using the Center for Epidemiologic Studies Depression Scale to Assess Depression in Women With HIV and Women at Risk for HIV: Are Somatic Items Invariant?

Leah M. Adams
George Mason University

Tracey E. Wilson
SUNY Downstate Medical Center School of Public Health

Daniel Merenstein
Georgetown University Medical Center

Joel Milam
University of Southern California, Los Angeles

Jennifer Cohen
University of California, San Francisco

Elizabeth T. Golub
Johns Hopkins University

Adebola Adedimeji
Albert Einstein College of Medicine

Judith A. Cook
University of Illinois at Chicago

The prevalence of depression among women living with HIV/AIDS is elevated, compared with women in the general population and men diagnosed with HIV/AIDS. Although symptoms of HIV may overlap with somatic symptoms of depression, little research has explored how well screening tools accurately assess depression rather than symptoms of HIV/AIDS among women. The present study examined the utility of a widely used tool for assessing depression symptoms among women living with HIV/AIDS. Data are from the Women's Interagency HIV Study (WIHS), a multisite, longitudinal cohort study of women living with HIV/AIDS ($n = 1,329$) and seronegative women ($n = 541$) matched on key risk factors for HIV/AIDS. Confirmatory factor analysis-based measurement invariance tests of the Center for Epidemiologic Studies Depression Scale (CES-D) were conducted to determine whether women with HIV and those without HIV responded to the scale similarly. Results supported measurement invariance of CES-D scores. Findings suggest that the CES-D can be used to assess for burden of depression symptoms among women diagnosed with HIV/AIDS.

Leah M. Adams, Department of Psychology and Women & Gender Studies Program, George Mason University; Tracey E. Wilson, Department of Community Health Services, SUNY Downstate Medical Center School of Public Health; Daniel Merenstein, Department of Family Medicine, Georgetown University Medical Center; Joel Milam, Department of Preventive Medicine, University of Southern California, Los Angeles; Jennifer Cohen, Department of Clinical Pharmacy, University of California, San Francisco; Elizabeth T. Golub, Department of Epidemiology, Johns Hopkins University; Adebola Adedimeji, Department of Epidemiology & Population Health, Albert Einstein College of Medicine; Judith A. Cook, Department of Psychiatry, University of Illinois at Chicago.

Data in this article were collected by the Women's Interagency HIV Study (WIHS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). WIHS (Principal Investigators: University of Alabama at Birmingham WIHS [Michael Saag, Mirjam-Colette Kempf, and Deborah Konkle-Parker], U01-AI-103401; Atlanta WIHS [Ighovwerha Oforokun and Gina Wingood], U01-AI-103408; Bronx WIHS [Kathryn Anastos], U01-AI-035004; Brooklyn WIHS [Howard Minkoff and Deborah Gustafson], U01-AI-031834; Chicago WIHS [Mardge Cohen and Audrey French], U01-AI-034993; Metropolitan Washington WIHS [Mary Young and Seble Kassaye], U01-AI-034994; Miami WIHS [Margaret Fischl and Lisa Metsch], U01-AI-103397; UNC WIHS [Adaora Adimora],

U01-AI-103390; Connie Wofsy Women's HIV Study, Northern California [Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien], U01-AI-034989; WIHS Data Management and Analysis Center [Stephen Gange and Elizabeth Golub], U01-AI-042590; Southern California WIHS [Joel Milam], U01-HD-032632 [WIHS I-WIHS IV]).

The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases, with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Mental Health. Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Deafness and other Communication Disorders, and the National Institutes of Health Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (University of California San Francisco Clinical and Translational Science Award) and UL1-TR000454 (Atlanta Clinical and Translational Science Award). The contribution of Dr. Adams was partially supported by Grant T32 AG027677 from the National Institute on Aging.

Correspondence concerning this article should be addressed to Leah M. Adams, MS 3f5, 4400 University Drive, Fairfax, VA 22030. E-mail: ladamse@gmu.edu

Public Significance Statement

This study suggests that, despite overlap in some symptoms of HIV and some symptoms of depression, scores on the Center for Epidemiologic Studies Depression Scale (CES-D) reflect symptoms of depression equally well for women who are HIV-positive and for women who are HIV-negative. This suggests that clinicians and researchers can meaningfully compare CES-D scores between women in these 2 groups.

Keywords: HIV/AIDS, somatic complaints, depression, women, measurement invariance

Depression is the leading neuropsychiatric complication in HIV-infected populations, with prevalence rates ranging between 20% and 40% (Centers for AIDS Research Social & Behavioral Science Research Network et al., 2011; Do et al., 2014; Nanni, Caruso, Mitchell, Meggiolaro, & Grassi, 2015; Rabkin, 2008). The prevalence of clinical depression among HIV-infected persons is two to four times higher than among the general population (Nanni et al., 2015). Mirroring the general population, higher rates of depression have been found in HIV-positive women compared with HIV-positive men (Cook et al., 2002; Ickovics et al., 2001; Nanni et al., 2015).

Biological and psychosocial factors are associated with clinical depression among HIV-infected individuals. Biologically, HIV virus may cause a release of inflammatory cytokines leading to cytokine-induced sickness behavior, which is similar to symptoms of depression (e.g., psychomotor retardation, anhedonia, appetite suppression; Kelley et al., 2003; Raedler, 2011). Further, HIV infection may alter tryptophan, which indirectly affects serotonin production (the neurotransmitter targeted by many antidepressant medications; Danzter, O'Connor, Lawson, & Kelley, 2011; Schroeksadel et al., 2008). Psychosocial factors experienced by many HIV-infected individuals such as marginalization, HIV-related stigma, social isolation, substance abuse, and trauma histories can lead to higher rates of depression (Centers for AIDS Research Social & Behavioral Science Research Network et al., 2011; Nanni et al., 2015).

Moderate to severe depression is associated with high-risk behaviors that contribute to increased risk of contracting HIV (Hutton, Lyketsos, Zenilman, Thompson, & Erbeling, 2004; O'Cleirigh et al., 2013). Depression severity is associated with faster disease progression, higher AIDS-related mortality, and decreased adherence to medication among HIV-infected women and men (Cook et al., 2002; Leserman et al., 2002). If screened and diagnosed, depression is often a treatable condition. Despite known links between HIV diagnosis and depression, those with both conditions often do not receive the treatment that they need. For instance, in the Women's Interagency HIV Study (WIHS), which serves as the platform for this analysis, fewer than half of women with diagnoses of both HIV and depression reported receiving adequate treatment for their depression (Cook et al., 2014).

The interpretations of a number of screening tools have been validated for use in primary care settings to assess symptoms of depression (Centers for AIDS Research Social & Behavioral Science Research Network et al., 2011), though few measures have been examined in HIV-infected populations. Consistent measurement across different groups is vital, as it forms the basis for

accurately interpreting results and comparing scores between people. There is reason to investigate whether measures of depression assess the disorder equally well in people with HIV relative to people without HIV. Adequate screening and differential diagnosis of depression among individuals with HIV may be complicated by somatic symptoms (e.g., concentration difficulties, appetite difficulties, sleep disturbance) that are common to both HIV and depression. Including somatic items in the assessment of individuals with HIV may result in misleadingly high estimates of depression, which are attributable to poor HIV disease management. Perkins and colleagues (1995) found that in their sample, asymptomatic HIV-positive homosexual men and HIV-negative homosexual men had similar levels of somatic complaints (specifically, insomnia and fatigue). They concluded that somatic complaints among asymptomatic HIV-positive individuals reflected true depression (Perkins et al., 1995). However, Kalichman, Rompa, and Cage (2000) reported among HIV-positive adults, removing somatic items from the Beck Depression Inventory and the Center for Epidemiologic Studies Depression Scale (CES-D) improved their clinical utility for symptomatic HIV-positive people by enhancing specificity in assessing symptoms indicative of depression.

Although these studies provide important information about the relationship between somatic symptoms and depression for adults with HIV, neither address whether somatic items on depression scales measure the same construct for women with and without HIV. Kalichman, Rompa, and Cage (2000) sample included only HIV-positive adults, a third of whom were women, whereas Perkins and colleagues' (1995) study was restricted to asymptomatic (HIV-positive and HIV-negative) men. Compared with men, women report somatic symptoms of depression at higher rates and are more likely to be classified through formal diagnostic criteria as having "somatic depression," in which at least three somatic symptoms are endorsed (Silverstein, 2002). This different pattern of symptom endorsement has been cited as a driving force of the gender imbalance in depression rates (Silverstein et al., 2013). Given the potential for somatic symptoms associated with HIV infection to elevate depression scores, along with women's tendency to endorse such symptoms at a higher rate, it is critical to explore the influence of somatic complaints on depression ratings among women with and without HIV, rather than solely comparing women with men. Such an investigation can determine whether assessment of depression, in general, and somatic symptoms of depression, in particular, is substantially different for HIV-positive and HIV-negative women; this may provide additional information about effective depression screening in HIV-positive women.

The goal of the current study was to psychometrically analyze a well-validated depression screening tool, the CES-D (Radloff, 1977), in HIV-positive and HIV-negative women, with an emphasis on somatic symptoms of depression. A multiple-group confirmatory factor analysis (CFA) approach was used to examine measurement invariance (configural, metric, scalar) across the two groups. On the basis of the somatic features associated with HIV infection, we expected scalar noninvariance for somatic items of depression, such that an HIV-positive woman with the same level of depression as an HIV-negative woman would be more likely to endorse somatic symptoms of depression (e.g., concentration difficulties, appetite problems), as measured by the CES-D.

Method

Participants

Participants were enrolled in the Women's Interagency HIV Study (WIHS), a multisite cohort study of HIV disease progression in women. Initial WIHS recruitment occurred at six U.S. sites: Brooklyn; Bronx; Chicago; Los Angeles; San Francisco/Bay Area; and Washington, DC. The sample is consistent with the demographic distribution of women with HIV in the United States, and primarily comprises African American (57.3%) and Hispanic/Latina women (27.3%). Women enrolled in WIHS provide written informed consent to participate in study visits every 6 months. These visits include self-report measures assessing demographic features, health status, psychosocial functioning, service utilization, physical and gynecological exams, and serologic and salivary samples. All WIHS study procedures have been approved by the institutional review boards at each site. Full details of the WIHS study are available elsewhere (Barkan et al., 1998; Bacon et al., 2005).

Data for the present analyses are derived from 1,870 women (71.1% HIV-positive, 28.9% HIV-negative) who completed the CES-D during a study visit occurring between October 1, 2006 and March 31, 2007 (see Table 1). This visit was chosen because it coincided with the introduction of a menopause questionnaire that assessed somatic and mental health complaints, which was used to compare somatic symptom endorsement with the depression measure.

Measures

Depression. Depression symptoms were assessed using the CES-D (Radloff, 1977). The CES-D is a 20-item self-report measure of depression symptoms and includes items that evaluate affective (e.g., depressed mood), cognitive (e.g., feelings of worthlessness), and somatic (e.g., loss of appetite) symptoms of depression. Each item is rated using a 4-point Likert scale to indicate how frequently the symptom occurred in the last week (0 = *rarely/less than 1 day*, 3 = *most of the time/5–7 days*). Four positively valenced items are reversed prior to scoring. Scores range from 0 to 60, with higher scores indicating a greater degree of depression symptoms. A cut-off score of ≥ 16 is a widely used indicator for likely clinically meaningful depressive symptoms (Radloff, 1977; Schulberg et al., 1985). The CES-D has been used extensively throughout community and clinical samples (Chwastiak, Ehde, Gibbons, Sullivan, Bowen, & Kraft, 2002; Ottenbacher et al.,

2012; Zimmerman & Coryell, 1994). The psychometric properties of the scale scores have generally been good, though the factor structure of the CES-D has been a subject of contention with varying numbers of factor solutions being reported and supported in the literature (Carleton et al., 2013) and with limited evidence of the unidimensionality of the full CES-D relative to a shortened version of the scale (Levine, 2013).

Auxiliary somatic and health symptoms. Additional somatic and affective questions were introduced in Visit 25 as part of a menopause stage and screening questionnaire (Rubin et al., 2014) used in the Study of Women's Health Across the Nation (SWAN). Thirteen questions assessed the frequency of experiencing each symptom (e.g., back pain, vaginal complaints, dizziness, sleep disturbance, memory concerns, mood disturbance, headaches) over the last 2 weeks on a Likert scale (1 = *not at all*, 2 = *1–5 days*, 3 = *6–8 days*, 4 = *9–13 days*, 5 = *every day*). We included these questions prior to CFAs as a check for participants' consistency in responding about somatic complaints and mood throughout the interview.

Data Analysis

Preliminary analyses explored attrition, variable distributions, sample characteristics, overlap between the CES-D and auxiliary somatic items, and simple correlations using SPSS Version 19 for Macintosh (IBM, 2010). In line with prior work demonstrating variable factor structures for the full 20-item CES-D, we tested one-, two-, and four-factor models (Carleton et al., 2013). All CFA models were analyzed using Mplus 7.1 (Muthén & Muthén, 1998–2012), and robust weighted least square mean and variance (WLSMV) estimation with theta parameterization was used to account for the categorical nature of the CES-D (Garrido, Abad, & Ponsoda, 2016).

Once the optimal number of factors was obtained, we used this model to assess for measurement invariance between HIV-positive and HIV-negative women. Consistent with Millsap and Yun-Tein's (2004) recommended procedure, measurement invariance was assessed in a series of progressively stringent steps. First, a configural model was tested to determine whether the same factor pattern was present in both groups (e.g., same number of factors with the same indicators) and whether it fit each group sufficiently well. In this baseline model, the factor loadings of the scaling indicators were set to 1 for both groups, the first two thresholds of the scaling indicators were constrained to be equal across both groups (the third threshold was free to vary across scaling indicators), the first threshold of the additional indicators were constrained to be equal across groups (with the other two free to vary), and residual variances were constrained in the HIV-negative group, whereas they were freely estimated in the HIV-positive group. Second, metric invariance was assessed such that factor loadings were constrained to be equal across both groups. If there is no difference in fit between the metric model and the configural model, then metric invariance is supported. Third, we tested scalar invariance by constraining item thresholds to be equal across groups; if the fit of this model is not significantly different from the fit of the metric model, then scalar invariance is supported. Although it is possible to assess for invariance between residual variances, many methodologists consider this to be impractical and overly stringent, thus we did not perform this test (Brown, 2006;

Table 1
Sample Descriptive Information

Characteristic	HIV-positive (<i>n</i> = 1,329)		HIV-negative (<i>n</i> = 541)	
	<i>M</i> or %	<i>SD</i> or <i>n</i>	<i>M</i> or %	<i>SD</i> or <i>n</i>
Age	44.0	8.7	40.2	10.1
Race/ethnicity				
Black (Non-Hispanic/Latino)	56.3	748	59.9	324
White (Non-Hispanic/Latino)	13.2	175	9.2	50
Hispanic/Latino	27.8	369	26.2	142
Asian/Pacific Islander	.6	8	1.5	8
Native American/Alaskan Native	.3	4	1.3	7
Other	1.9	25	1.8	10
Highest level of education				
None	.7	9	.2	1
Completed Grades 1–6	5.5	73	.9	5
Completed Grades 7–11	33.0	438	34.2	184
Completed high school (Grade 12)	29.2	387	32.9	177
Some college	24.3	323	25.1	135
Completed college (4 years)	5.4	71	5.4	29
Attended/completed graduate school	2.0	26	1.3	7
Marital status				
Never married	30.5	405	40.3	218
Legally/common-law married	21.2	282	21.4	116
Not married, living with partner	9.9	132	10.9	59
Divorced/annulled	11.5	153	6.5	35
Separated	9.6	128	9.1	49
Widowed	10.9	145	5.2	28
Other	6.3	83	6.7	36
Overall Depression score (CES-D)	13.7	12.8	13.1	12.3
Somatic Symptoms Depression score (CES-D)	5.5	5.0	5.4	4.7
Menopause Symptoms Questionnaire				
Back pain	2.2	1.4	2.1	1.4
Vaginal dryness	1.4	1.0	1.3	.8
Feeling “blue” or depressed	1.9	1.2	1.8	1.1
Dizzy spells	1.3	.7	1.2	.6
Forgetfulness	1.8	1.2	1.7	1.1
Frequent mood changes	1.9	1.2	1.9	1.4
Heart pounding or racing	1.4	.9	1.4	.8
Feeling fearful for no reason	1.3	.8	1.2	.7
Headaches	1.7	1.0	1.6	.9
Breast pain/tenderness	1.2	.7	1.2	.7
Vaginal irritation/itching	1.2	.7	1.2	.6
Vaginal discharge	1.2	.7	1.3	.8
Vaginal soreness/pain	1.2	.6	1.1	.5
Trouble falling asleep	2.3	1.6	2.2	1.5
Waking up several times per night	3.0	1.6	2.7	1.6
Waking up earlier than planned	2.5	1.6	2.2	1.5
Sleep quality	2.2	1.0	2.1	.9

Note. Menopause questions are rated for last 2 weeks on a 5-point scale (1 = *not at all*, 5 = *everyday*). Sleep quality item refers to past month on 4-point scale (1 = *very good*, 4 = *very bad*).

Raju, Laffitte, & Byrne, 2002). If invariance is not supported at any step (e.g., metric, scalar), the source of noninvariance can be determined by examining modification indices provided by Mplus, and freeing constrained parameters (e.g., loadings, thresholds) until partial invariance is satisfied at that level. Additional analyses were conducted in a subsample of HIV-positive women in which measurement invariance was assessed between women likely to be symptomatic (CD4 count <200) and asymptomatic (CD4 count >200).

Goodness of fit was evaluated using several indices because they provide unique and balancing information when examining model fit (e.g., absolute fit, relative fit, adjustments for parsimony).

A model is considered to fit the data well when there is a statistically nonsignificant chi-square statistic, a root mean square error of approximation (RMSEA) below 0.06, and a comparative fit index (CFI) or Tucker–Lewis Index (TLI) above 0.95 (Hu & Bentler, 1999). Bayesian information criterion (BIC) values provide another method of comparing non-nested models, though they are unavailable when using the WLSMV estimator. We computed BIC values to compare the competing factor models using maximum likelihood estimation and present this information alongside fit values obtained from the WLSMV estimator. To statistically compare models, the DIFFTEST option for WLSMV estimators, which relies on robust chi square tests, was used because standard

chi-square difference tests do not provide accurate estimates with categorical predictors (Asparouhov & Muthén, 2006). However, some researchers have found that changes in CFI and RMSEA provide better comparisons between nested models than chi square difference tests due to the influence that sample size has on the chi square statistic and on its tendency to be upwardly biased, resulting in rejecting correctly specified models in large samples (Meade, Johnson, & Braddy, 2008; Savalei & Rhemtulla, 2013). Generally, $\Delta CFI < .01$ and $\Delta RMSEA < .015$ supports invariance. Given the strengths and weaknesses of each fit index, we examined measurement invariance using all three indices.

Results

Inclusion–Exclusion Comparisons

In preliminary analyses, we examined whether participants with depression data at Visit 25 ($n = 1,870$) differed in substantive ways from those who were excluded from analyses due to missing depression data ($n = 208$). The women with depression data were slightly younger ($M = 42.90, SD = 9.28$) than those without it ($M = 44.37, SD = 9.86$), $t(2076) = 2.14, p = .03$. The two groups did not differ with regard to HIV status, marital status, race/ethnicity, level of education, or on any other auxiliary somatic symptom indicators (all $ps > .17$).

Sample Description

Table 1 provides a full description of the analytic sample. HIV-positive women in the sample were, on average, 44 years old ($SD = 8.7$, range: 23–78) and the HIV-negative women were, on average, 40 years old ($SD = 10.1$, range: 23–74). Women in either group were most likely to have completed Grades 7 through 11 (HIV-positive: 33.0%; HIV-negative: 34.2%), completed high school (HIV-positive: 29.2%; HIV-negative: 32.9%), or completed some college (HIV-positive: 24.3%; HIV-negative: 25.1%). Small proportions of women in either group reported having no education or reported completing college. With regard to relationship status, the greatest proportion of women reported having never been married (HIV-positive: 30.5%; HIV-negative: 40.3%) or being legally/common-law married (HIV-positive: 21.2%; HIV-negative: 21.4%).

Prevalence of Depressive Symptoms and Auxiliary Somatic Complaints

Mean depressive symptom scores for HIV-positive ($n = 1,329$; $M = 13.74, SD = 12.82$, range: 0–59) and HIV-negative ($n = 531$; $M = 13.12, SD = 12.29$, range: 0–59) women were comparable, $t(1,868) = -0.96, p = .34$ (see Table 1). More than a third of HIV-positive (37.3%) and HIV-negative (33.5%) women were classified as having likely depression (CES-D ≥ 16) at Visit 25. HIV-positive ($M = 5.46, SD = 4.96$, range: 0–21) and HIV-negative ($M = 5.36, SD = 4.71$, range: 0–21) women did not differ with regard to endorsing the items that assess somatic symptoms of depression, $t(1,868) = -0.40, p = .69$.

To examine consistency in responding to questions about depression and somatic complaints, we conducted correlations between the CES-D total depression score, CES-D somatic items

score, and the auxiliary somatic complaints of the menopause questionnaire. Both the CES-D total depression score ($r = .72, p < .001$) and CES-D somatic items summed score ($r = .63, p < .001$) showed the strongest association with participants’ response to the menopause questionnaire item addressing feeling “blue or depressed.” Beyond this, the total CES-D depression score was most related to mood changes ($r = .53, p < .001$), feeling fearful for no reason ($r = .46, p < .001$), and forgetfulness ($r = .45, p < .001$). The CES-D somatic items were primarily associated with mood changes ($r = .49, p < .001$), forgetfulness ($r = .43, p < .001$), and poor sleep quality ($r = .42, p < .001$).

Dimensionality of the CES-D

Consistent with findings from earlier studies suggesting a variety of well-fitting factor structures for the full 20-item CES-D, we examined single-factor, two-factor, and four-factor solutions to assess the underlying dimensionality of the measure (see Table 2). A single factor CFA demonstrated poor model fit, $\chi^2(170) = 3318.02, p < .001, RMSEA = .099$ [90% CI: .096–.102], CFI = .932, TLI = .924, BIC = 90555.90. A two-factor solution, modeling a general depression factor and a positive affect factor demonstrated adequate fit, $\chi^2(169) = 1476.35, p < .001, RMSEA = .064$ [90% CI: .061–.067], CFI = .972, TLI = .968, BIC = 89555.81. A four-factor solution including general depression, positive affect, somatic symptoms, and interpersonal problems factors provided the best fit to the data, $\chi^2(164) = 1106.87, p < .001, RMSEA = .055$ [90% CI: .052–.058], CFI = .980, TLI = .977, BIC = 89273.52. The four-factor solution demonstrated a significant improvement in fit over the two-factor solution, $\Delta\chi^2(5) = 247.90, p < .001$. Modification indices in the four-factor model suggested that the residuals between “crying spells” and “felt sad” on the affective depression factor be de-

Table 2
Item Mapping for Tested Models

Item	One-factor	Two-factors	Four-factors
1. Bothered by things ^a	DA	DA	SC
2. Appetite was poor	DA	DA	SC
3. Can't shake off the blues ^a	DA	DA	DA
4. Just as good as others ^a	DA	PA	PA
5. Trouble concentrating	DA	DA	SC
6. Felt depressed	DA	DA	DA
7. Everything was an effort	DA	DA	SC
8. Hopeful about the future	DA	PA	PA
9. Life has been a failure	DA	DA	DA
10. Fearful	DA	DA	DA
11. Sleep was restless	DA	DA	SC
12. Happy	DA	PA	PA
13. Talked less than usual	DA	DA	SC
14. Felt lonely	DA	DA	DA
15. People were unfriendly ^a	DA	DA	IP
16. Enjoyed life	DA	PA	PA
17. Had crying spells	DA	DA	DA
18. Felt sad	DA	DA	DA
19. People disliked me	DA	DA	IP
20. Could not get going	DA	DA	SC

Note. DA = depressed affect; PA = positive affect; SC = somatic complaints; IP = interpersonal problems.
^a Scaling indicator.

clared; this resulted in an improved model, $\chi^2(163) = 867.43$, $p < .001$, RMSEA = .048 [90% CI: .045–.051], CFI = .985, TLI = .982, $\Delta\chi^2(1) = 153.30$, $p < .001$. Thus, this final four-factor model was retained for all measurement invariance analyses. McDonald's (1999) omega was used to estimate the reliability coefficients of each factor's scores. Reliability estimates were acceptable for the somatic ($\omega = .875$), affective depression ($\omega = .944$), positive affect ($\omega = .870$), and interpersonal ($\omega = .850$) factors' scores.

The four-factor model was fitted for both HIV-positive and HIV-negative women. The fit values for HIV-positive women were, $\chi^2(163) = 688.53$, $p < .001$, RMSEA = .049 [90% CI: .045–.053], CFI = .984, TLI = .982. For HIV-negative women, the values were, $\chi^2(163) = 355.48$, $p < .001$, RMSEA = .047 [90% CI: .040–.053], CFI = .985, TLI = .983. Although the WLSMV chi-square values suggested poor fit, the remaining fit indices indicated good fit for both groups of women. Table 3 displays the standardized factor loadings and thresholds for HIV-positive and HIV-negative women for this solution.

Measurement Invariance

HIV-positive versus HIV-negative women. The fit indices for the configural model were, $\chi^2(326) = 1011.37$, $p < .001$, RMSEA = .047 [90% CI: .044–.051], CFI = .985, TLI = .983, with the chi-square value indicating poor fit and the other indices demonstrating good fit. Taken together, these findings suggest that the CES-D has the same pattern of item-factor loadings for women with and without HIV. For the full metric invariance model, the fit indices were, $\chi^2(344) = 1178.97$, $p < .001$, RMSEA = .051 [90%

CI: .048–.054], CFI = .982, TLI = .980. Although the chi-square difference test results were statistically significant, $\Delta\chi^2(18) = 148.46$, $p < .001$, between the configural and metric models, the changes in CFI ($\Delta\text{CFI} = -.003$) and RMSEA ($\Delta\text{RMSEA} = .004$) supported invariance and suggest that the unstandardized factor loadings on the CES-D were comparable for HIV-positive women and HIV-negative women. The full scalar invariance model resulted in the following fit, $\chi^2(380) = 1108.49$, $p < .001$, RMSEA = .045 [90% CI: .042–.048], CFI = .985, TLI = .985. All three change indexes supported invariance in threshold loadings on the CES-D between HIV-positive and HIV-negative women, $\Delta\chi^2(36) = 47.73$, $p = .09$, $\Delta\text{CFI} = .003$, $\Delta\text{RMSEA} = -.006$.

HIV-positive women: Symptomatic versus asymptomatic. We also tested measurement invariance across HIV-positive women who were likely to be symptomatic (CD4 count < 200) and those likely to be asymptomatic (CD4 count > 200). The fit indices for the configural model were, $\chi^2(326) = 775.47$, $p < .001$, RMSEA = .046 [90% CI: .042–.050], CFI = .985, TLI = .983, with the chi-square value indicating poor fit and the other indices suggesting good fit. For the full metric invariance model, the fit indices were, $\chi^2(344) = 841.51$, $p < .001$, RMSEA = .047 [90% CI: .043–.051], CFI = .984, TLI = .982. Although the chi-square difference test results were statistically significant, $\Delta\chi^2(18) = 75.16$, $p < .001$, between the configural and metric models, the changes in CFI ($\Delta\text{CFI} = -.001$) and RMSEA ($\Delta\text{RMSEA} = .001$) supported invariance and suggest that the unstandardized factor loadings on the CES-D were comparable for HIV-positive women likely to be symptomatic (CD4 < 200) and those likely to be asymptomatic (CD4 > 200). The full scalar invariance model

Table 3
Standardized Factor Loadings and Thresholds for the Four-Factor Model for HIV-Positive and HIV-Negative Women

CES-D item	HIV-positive				HIV-negative			
	λ	τ_1	τ_2	τ_3	λ	τ_1	τ_2	τ_3
Somatic complaint								
1. Bothered by things	.79	.26	.87	1.27	.75	.20	.81	1.18
2. Poor appetite	.68	.35	.95	1.33	.63	.54	1.17	1.49
5. Trouble concentrating	.77	.15	.87	1.32	.79	.18	.87	1.26
7. Everything was an effort	.58	-.06	.46	.74	.41	-.13	.34	.62
11. Restless sleep	.70	-.15	.50	.90	.70	-.12	.55	.93
13. Talked less than usual	.67	.29	.96	1.36	.60	.32	.81	1.28
20. Could not get going (amotivation)	.82	.28	.99	1.33	.84	.48	1.10	1.50
Depressed affect								
3. Could not shake the blues	.89	.94	1.35	1.41	.89	.36	1.02	1.41
6. Felt depressed	.90	.09	.82	1.13	.91	.13	.74	1.21
9. My life had been a failure	.81	.62	1.20	1.55	.82	.71	1.19	1.50
10. I felt fearful	.79	.53	1.22	1.53	.77	.68	1.27	1.68
14. Felt lonely	.80	.23	.87	1.20	.79	.30	.94	1.26
17. Crying spells	.82	.37	1.02	1.38	.81	.44	.94	1.35
18. Felt sad	.92	.07	.90	1.21	.91	.11	.83	1.26
Positive affect								
4. Just as good as others	.68	.72	1.17	1.34	.61	.54	.81	1.34
8. Hopeful about future	.66	.21	.56	1.17	.73	.32	.70	1.17
12. I was happy	.95	.11	.52	1.23	.92	.14	.57	1.21
16. I enjoyed life	.83	.36	.72	1.36	.84	.46	.86	1.50
Interpersonal problems								
15. People unfriendly	.82	.62	1.28	1.59	.77	.70	1.28	1.72
19. Felt people disliked me	.92	.73	1.30	1.59	.92	.76	1.27	1.63

Note. CES-D = Center for Epidemiologic Studies Depression Scale; λ = factor loading; τ = threshold.

resulted in the following fit: $\chi^2(380) = 836.63$, $p < .001$, RMSEA = .043 [90% CI: .039–.047], CFI = .985, TLI = .985. Consistent with the model comparing women with and without HIV, all three change indexes supported invariance in threshold loadings on the CES-D between likely asymptomatic and likely symptomatic HIV-positive women, $\Delta\chi^2(36) = 46.70$, $p = .11$, $\Delta CFI = .001$, $\Delta RMSEA = -.004$.

Discussion

This study assessed the psychometric properties of a widely used depression screening measure, the CES-D, in a mixed sample of HIV-infected women and HIV-negative women matched on key risk factors for HIV. Our results supported the four-factor model of the CES-D, relative to a two-factor and one-factor model, which is consistent with a preponderance, though not all, of other studies' findings (Carleton et al., 2013). The primary goal of the present study was to examine whether the CES-D assessed depression equivalently in women with and without HIV. In our examination of measurement invariance across these groups, we found that the CES-D scores were invariant across HIV-positive and HIV-negative women. Additional analyses demonstrated that CES-D scores were also invariant across HIV-positive women who were likely symptomatic (CD4 count <200) and HIV-positive women who were likely asymptomatic (CD4 count >200).

To our knowledge, this is the first psychometric evaluation of measurement invariance of the CES-D in a mixed sample of HIV-positive and HIV-negative women. Prior work examining the influence of somatic complaints on depression scores among HIV-positive adults have relied on correlational and regression-based analyses, which cannot provide information about the item-level true scores or identify sources of noninvariance in the way that CFA can. Further, prior work has focused only on HIV-positive adults (Kalichman et al., 2000) has excluded women (Perkins et al., 1995) or have limited their assessment of somatic symptoms (Perkins et al., 1995).

Our findings of measurement invariance, though distinct, echo some important recommendations from previous works' implications. Perkins and colleagues (1995) cautioned against automatically attributing somatic complaints from HIV-positive adults to their HIV-infection without considering the potential for depression. Our results demonstrated that items assessed via the CES-D, including those assessing somatic complaints, operated equivalently for women with and without HIV, and for HIV-positive women with likely asymptomatic and symptomatic presentations. Thus, on the basis of our findings, clinicians and researchers can infer that scores on the CES-D for HIV-positive women can be compared with CES-D scores for HIV-negative women. Our results provide evidence that HIV-positive and HIV-negative women were responding to the CES-D in equivalent manners and that they were endorsing comparable response categories for roughly equivalent levels of depression, across the factors assessed by the CES-D. Still, it is important to note that our findings do not explain the cause of depression among women with or without HIV. Our findings do not suggest that somatic complaints associated with HIV bear no influence on symptoms of depression among HIV-positive women. It may be the case that somatic complaints associated with HIV/AIDS contribute to depression symptoms, including somatic complaints of depression, even with measurement

invariance of somatic item scores across HIV-positive and HIV-negative women.

Limitations

Our results should be interpreted in light of several limitations. The CES-D is a widely used instrument, but it is not the sole instrument used in assessing symptoms of depression. Our findings relate to the psychometric properties of the CES-D with a sample of HIV-positive women, but may not reflect the properties of other widely used depression instruments. Further, we relied on CFA-based measurement invariance tests to assess whether the CES-D operated differently for women with and without HIV. Other methods, such as item-response theory with tests of differential item functioning, exist to examine the same phenomenon. Although our findings supported measurement invariance, an IRT-based analysis could find instances of differential item functioning because of differences in how both methods approach this question (e.g., linear vs. nonlinear models; see Raju et al., 2002). Thus, our results do not represent the final declaration of measurement equivalence in assessing depression in women with and without HIV.

The demographic composition of WIHS participants reflects the face of HIV among U.S. women. However, this is not a representative sample, and our results may not generalize to women with and at risk for HIV who live in other parts of the country or who are unable to participate in WIHS. Generally, rates of depression are higher among HIV-positive women than among HIV-negative women. In our sample, HIV-positive and HIV-negative women reported equivalent levels of depression symptoms. Work examining depression in representative samples highlights the heightened prevalence of depression among women, low-income adults, and ethnic and racial minorities, with all of these factors operating in tandem (Jackson-Triche et al., 2000; Walsh, Levine, & Levay, 2012). Given that the HIV-negative women in the sample represent women at-risk for HIV, many of whom have additional psychosocial stressors, their depression scores may be elevated and not be generalizable to other HIV-negative women. Likewise, HIV-positive women in our sample might be healthier than HIV-positive women not involved in WIHS, given that many of the women in WIHS are linked to active HIV care. Further, these results are specific to the role of HIV in symptoms of depression and may not generalize to women living with different medical illnesses. Separate investigations with those populations should be conducted.

Our investigation focused on women to the exclusion of men. Although it is critical to understand how HIV-status may affect the measurement of depression using rating scales in women, it is also important to understand how gender and HIV-status may function jointly and separately to differentially influence assessment of depression. Future work should examine measurement invariance of CES-D scores in a sample of HIV-positive and HIV-negative men and women to determine whether comparisons of CES-D scores across these four groups are appropriate.

Conclusions

The burden of depression is significant among women in the United States. Over one third of the women in our sample, HIV-

positive and HIV-negative, reported elevated and clinically relevant symptoms of depression, which may translate into extended periods of treatable suffering, financial burden, and negative health impact. This study used CFA to examine measurement invariance in the assessment of depression symptoms among women with and without HIV. Further, it extends the literature regarding the psychometric and measurement properties of CES-D scores, which are used extensively in research and in clinical practice. Our analyses provide encouraging support for the use of the CES-D to examine symptoms of depression among HIV-positive women. The finding of measurement invariance suggests that comparisons of CES-D scores between HIV-positive and HIV-negative women are meaningful.

References

- Asparouhov, T., & Muthén, B. (2006, May 26). *Robust chi-square difference testing with mean and variance adjusted test statistics* (Mplus Web Notes No. 10). Retrieved from <https://www.statmodel.com/download/webnotes/webnote10.pdf>
- Bacon, M. C., von Wyl, V., Alden, C., Sharp, G., Robison, E., Hessel, N., . . . Young, M. A. (2005). The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. *Clinical and Diagnostic Laboratory Immunology*, *12*, 1013–1019.
- Barkan, S. E., Melnick, S. L., Preston-Martin, S., Weber, K., Kalish, L. A., Miotti, P., . . . the WIHS Collaborative Study Group. (1998). The Women's Interagency HIV Study. WIHS collaborative study group. *Epidemiology*, *9*, 117–125. <http://dx.doi.org/10.1097/00001648-199803000-00004>
- Brown, T. A. (2006). *Confirmatory factor analysis for applied research*. New York, NY: Guilford Press.
- Carleton, R. N., Thibodeau, M. A., Teale, M. J. N., Welch, P. G., Abrams, M. P., Robinson, T., & Asmundson, G. J. G. (2013). The center for Epidemiologic Studies Depression Scale: A review with a theoretical and empirical examination of item content and factor structure. *PLoS ONE*, *8*(3), e58067. <http://dx.doi.org/10.1371/journal.pone.0058067>
- Centers for AIDS Research Social and Behavioral Science Research Network, Simoni, J. M., Safren, S. A., Manhart, L. E., Lyda, K., Grossman, C. I., . . . Wilson, I. B. (2011). Challenges in addressing depression in HIV research: Assessment, cultural context, and methods. *AIDS and Behavior*, *15*, 376–388.
- Chwastiak, L., Ehde, D. M., Gibbons, L. E., Sullivan, M., Bowen, J. D., & Kraft, G. H. (2002). Depressive symptoms and severity of illness in multiple sclerosis: Epidemiologic study of a large community sample. *American Journal of Psychiatry*, *159*, 1862–1868.
- Cook, J. A., Burke-Miller, J. K., Grey, D. D., Cocohoba, J., Liu, C., Schwartz, R. M., . . . Cohen, M. H. (2014). Do HIV-positive women receive depression treatment that meets best practice guidelines? *AIDS and Behavior*, *18*, 1094–1102. <http://dx.doi.org/10.1007/s10461-013-0679-6>
- Cook, J. A., Cohen, M. H., Burke, J., Grey, D., Anastos, K., Kirstein, L., . . . Young, M. (2002). Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. *Journal of Acquired Immune Deficiency Syndromes*, *30*, 401–409. <http://dx.doi.org/10.1097/00042560-200208010-00005>
- Danzter, R., O'Connor, J. C., Lawson, M. A., Kelley, K. W. (2011). Inflammation-associated depression: from serotonin to kynurenine. *Psychoneuroendocrinology*, *36*, 426–436. <http://dx.doi.org/10.1016/j.psyneuen.2010.09.012>
- Do, A. N., Rosenberg, E. S., Sullivan, P. S., Beer, L., Strine, T. W., Schulden, J. D., . . . Skarbinski, J. (2014). Excess burden of depression among HIV-infected persons receiving medical care in the United States: Data from the medical monitoring project and the behavioral risk factor surveillance system. *PLoS ONE*, *9*(3), e92842.
- Garrido, L. E., Abad, F. J., & Ponsoda, V. (2016). Are fit indices really fit to estimate the number of factors with categorical variables? Some cautionary findings via Monte Carlo simulation. *Psychological Methods*, *21*, 93–111. <http://dx.doi.org/10.1037/met0000064>
- Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Structural Equation Modeling*, *6*, 1–55. <http://dx.doi.org/10.1080/10705519909540118>
- Hutton, H. E., Lyketsos, C. G., Zenilman, J. M., Thompson, R. E., & Erbeling, E. J. (2004). Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. *The American Journal of Psychiatry*, *161*, 912–914. <http://dx.doi.org/10.1176/appi.ajp.161.5.912>
- IBM. (2010). IBM SPSS Statistics for Macintosh (Version 19.0) [Computer software]. Armonk, NY: Author.
- Ickovics, J. R., Hamburger, M. E., Vlahov, D., Schoenbaum, E. E., Schuman, P., Boland, R. J., . . . HIV Epidemiology Research Study Group. (2001). Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. *Journal of the American Medical Association*, *285*, 1466–1474.
- Jackson-Triche, M. E., Greer Sullivan, J., Wells, K. B., Rogers, W., Camp, P., & Mazel, R. (2000). Depression and health-related quality of life in ethnic minorities seeking care in general medical settings. *Journal of Affective Disorders*, *58*, 89–97. [http://dx.doi.org/10.1016/S0165-0327\(99\)00069-5](http://dx.doi.org/10.1016/S0165-0327(99)00069-5)
- Kalichman, S. C., Rompa, D., & Cage, M. (2000). Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. *Journal of Nervous and Mental Disease*, *188*, 662–670. <http://dx.doi.org/10.1097/00005053-200010000-00004>
- Kelley, K. W., Bluthé, R. M., Dantzer, R., Zhou, J. H., Shen, W. H., Johnson, R. W., & Broussard, S. R. (2003). Cytokine-induced sickness behavior. *Brain, Behavior, and Immunity*, *17*(Suppl. 1), S112–S118. [http://dx.doi.org/10.1016/S0889-1591\(02\)00077-6](http://dx.doi.org/10.1016/S0889-1591(02)00077-6)
- Leserman, J., Petitto, J. M., Gu, H., Gaynes, B. N., Barroso, J., Golden, R. N., . . . Evans, D. L. (2002). Progression to AIDS, a clinical AIDS condition and mortality: Psychosocial and physiological predictors. *Psychological Medicine*, *32*, 1059–1073. <http://dx.doi.org/10.1017/S0033291702005949>
- Levine, S. Z. (2013). Evaluating the seven-item Center for Epidemiologic Studies Depression Scale short-form: A longitudinal U.S. community study. *Social Psychiatry and Psychiatric Epidemiology*, *48*, 1519–1526. <http://dx.doi.org/10.1007/s00127-012-0650-2>
- McDonald, R. P. (1999). *Test theory: A unified treatment*. Mahwah, NJ: Lawrence Erlbaum.
- Meade, A. W., Johnson, E. C., & Braddy, P. W. (2008). Power and sensitivity of alternative fit indices in tests of measurement invariance. *Journal of Applied Psychology*, *93*, 568–592.
- Millsap, R. E., & Yun-Tein, J. (2004). Assessing factorial invariance in ordered-categorical measures. *Multivariate Behavioral Research*, *39*, 479–515. http://dx.doi.org/10.1207/S15327906MBR3903_4
- Muthén, L. K., & Muthén, B. O. (1998–2010). Mplus 7.1 [Computer software]. Los Angeles, CA: Author.
- Nanni, M. G., Caruso, R., Mitchell, A. J., Meggiolaro, E., & Grassi, L. (2015). Depression in HIV infected patients: A review. *Current Psychiatry Reports*, *17*, 530–541. <http://dx.doi.org/10.1007/s11920-014-0530-4>
- O'Cleirigh, C., Newcomb, M. E., Mayer, K. H., Skeer, M., Traeger, L., & Safren, S. A., & the Cross-Site Depression Prevention for Positives Team. (2013). Moderate levels of depression predict sexual transmission risk in HIV-infected MSM: A longitudinal analysis of data from six sites

- involved in a “prevention for positives” study. *AIDS and Behavior*, *17*, 1764–1769. <http://dx.doi.org/10.1007/s10461-013-0462-8>
- Ottenbacher, K. J., Graham, J. E., Ottenbacher, A. J., Lee, J., Al Snih, S., Karmarkar, A., . . . Ostir, G. V. (2012). Hospital readmission in persons with stroke following postacute inpatient rehabilitation. *Journal of Gerontology*, *67*, 875–881. <http://dx.doi.org/10.1093/gerona/67.4.875>
- Perkins, D. O., Leserman, J., Stern, R. A., Baum, S. F., Liao, D., Golden, R. N., & Evans, D. L. (1995). Somatic symptoms and HIV infection: Relationship to depressive symptoms and indicators of HIV disease. *The American Journal of Psychiatry*, *152*, 1776–1781. <http://dx.doi.org/10.1176/ajp.152.12.1776>
- Rabkin, J. G. (2008). HIV and depression: 2008 review and update. *Current HIV/AIDS Reports*, *5*, 163–171.
- Radloff, L. S. (1977). The CES-D Scale: A Self-Report Depression Scale for research in the general population. *Applied Psychological Measurement*, *1*, 385–401. <http://dx.doi.org/10.1177/014662167700100306>
- Raedler, T. J. (2011). Inflammatory mechanisms in major depressive disorder. *Current Opinion in Psychiatry*, *24*, 519–525.
- Raju, N. S., Laffitte, L. J., & Byrne, B. M. (2002). Measurement equivalence: A comparison of methods based on confirmatory factor analysis and item response theory. *Journal of Applied Psychology*, *87*, 517–529. <http://dx.doi.org/10.1037/0021-9010.87.3.517>
- Rubin, L. H., Sundermann, E. E., Cook, J. A., Martin, E. M., Golub, E. T., Weber, K. M., . . . Maki, P. M. (2014). An investigation of menopausal stage and symptoms on cognition in HIV-infected women. *Menopause*, *21*, 997–1006. <http://dx.doi.org/10.1097/GME.0000000000000203>
- Savalei, V., & Rhemtulla, M. (2013). The performance of robust test statistics with categorical data. *British Journal of Mathematical & Statistical Psychology*, *66*, 201–223. <http://dx.doi.org/10.1111/j.2044-8317.2012.02049.x>
- Schroeksnadel, K., Sarceletti, M., Winkler, C., Mumelter, B., Weiss, G., Fuchs, D., . . . Zangerle, R. (2008). Quality of life and immune activation in patients with HIV-infection. *Brain, Behavior, and Immunity*, *22*, 881–889. <http://dx.doi.org/10.1016/j.bbi.2007.12.011>
- Schulberg, H. C., Saul, M., McClelland, M., Ganguli, M., Christy, W., & Frank, R. (1985). Assessing depression in primary medical and psychiatric practices. *Archives of General Psychiatry*, *42*, 1164–1170. <http://dx.doi.org/10.1001/archpsyc.1985.01790350038008>
- Silverstein, B. (2002). Gender differences in the prevalence of somatic versus pure depression: A replication. *The American Journal of Psychiatry*, *159*, 1051–1052. <http://dx.doi.org/10.1176/appi.ajp.159.6.1051>
- Silverstein, B., Edwards, T., Gamma, A., Ajdacic-Gross, V., Rossler, W., & Angst, J. (2013). The role played by depression associated with somatic symptomatology in accounting for the gender difference in the prevalence of depression. *Social Psychiatry and Psychiatric Epidemiology*, *48*, 257–263. <http://dx.doi.org/10.1007/s00127-012-0540-7>
- Simoni, J. M., Safren, S. A., Manhart, L. E., Lyda, K., Grossman, C. I., Rao, D., . . . Wilson, I. B. (2011). Challenges in addressing depression in HIV research: Assessment, cultural context, and methods. *AIDS and Behavior*, *15*, 376–388. <http://dx.doi.org/10.1007/s10461-010-9836-3>
- Walsh, S. D., Levine, S. Z., & Levav, I. (2012). The association between depression and parental ethnic affiliation and socioeconomic status: A 27-year longitudinal US community study. *Social Psychiatry and Psychiatric Epidemiology*, *47*, 1153–1158. <http://dx.doi.org/10.1007/s00127-011-0424-2>
- Yu, C. Y., & Muthén, B. (2002). *Evaluation of model fit indices for latent variable models with categorical and continuous outcomes*. Paper presented at Proceedings of the Annual Meeting of the American Educational Research Association, New Orleans, LA.
- Zimmerman, M., & Coryell, W. (1994). Screening for major depressive disorder in the community: A comparison of measures. *Psychological Assessment*, *6*, 71–74. <http://dx.doi.org/10.1037/1040-3590.6.1.71>

Received July 10, 2016

Revision received January 11, 2017

Accepted January 12, 2017 ■